Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MT400 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MT 400, naproxen sodium 550mg |
| Name | Type | Description |
|---|---|---|
| MT400 | DRUG | MT 400, naproxen sodium 550mg |
Inclusion Criteria: 1. Male or female subjects who are 18-35 years of age at the screening visit 2. Female subjects are eligible for participation in the study if they are of: 1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or, 2. Childbearing potential,...
MT400 is an investigational small molecule developed by GSK plc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific therapeutic indication for MT400 has not been disclosed, and the compound remains in early clinical development rather than being an approved medicine.
MT400 is made and developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 study of MT400 conducted in the United States. The company holds the development program for this investigational small molecule asset.
MT400 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. Because only early-stage testing has been conducted, MT400 is investigational and has not been approved by the FDA for any indication.
MT400 has been evaluated in one completed Phase 1 trial, NCT00596245. That study was an open-label, placebo-controlled, parallel group trial in healthy volunteers assessing the effects of two single MT400 or naproxen sodium tablets. It enrolled 42 participants in the United States.
The MT400 Phase 1 trial, NCT00596245, was an open-label, placebo-controlled, parallel group study in healthy volunteers. It enrolled 42 participants aged 18 years and older of all sexes in the United States. The study compared two single MT400 or naproxen sodium tablets and has been completed.